Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Since March 2019, a non-communicable diseases program has been established at hospital level, with enrollment and clinical reassessment every 6 months. Since July 2023, monthly enrollment and visits have also been conducted at health center level. This study aimed at assessing the adherence to scheduled follow-up visits following the decentralization of the integrated NCDs program from Hospital to Health Center level and investigate factors influencing follow-up adherence. The study was performed in a rural district in Iringa Region, Tanzania. Adherence was measured at both levels. Multivariate regression analysis was conducted to describe socio-demographic and clinical factors influencing attendance at the 6-month hospital-level visit. Among 2198 patients enrolled at the hospital level, weighted adherence over 42 months was 40.8% (95% CI 39.0-42.6%) at the 6-month visit. Multivariate analysis revealed that as the distance from the hospital increased, the probability of attendance decreased (OR 0.17; 95% CI: 0.08-0.39). Among 571 patients enrolled at the residence level, adherence over the first 10 months of program implementation was 91.6% (90.4-92.8%). The findings showed that distance was by far the most important barrier to follow-up adherence and suggested that decentralizing the program from the hospital to peripheral health centers may ensure high follow-up rates.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11594252PMC
http://dx.doi.org/10.3390/ijerph21111506DOI Listing

Publication Analysis

Top Keywords

non-communicable diseases
8
hospital level
8
health center
8
center level
8
program hospital
8
factors influencing
8
follow-up adherence
8
patients enrolled
8
adherence months
8
adherence
7

Similar Publications

The WHO global landscape of cancer clinical trials.

Nat Med

September 2025

Emerging Technology, Research Prioritization and Support Unit, Department of Research for Health, World Health Organization, Geneva, Switzerland.

Clinical trials are essential to advancing cancer control, yet access and participation remain unequal globally. The World Health Organization (WHO) established the International Clinical Trials Registry Platform (ICTRP) to enable a complete view of interventional clinical research for all those involved in healthcare decision-making and to identify actionable goals to equitable participation at the global level. A review of 89,069 global cancer clinical trials registered in the WHO ICTRP between 1999 and December 2022 revealed a cancer clinical trial landscape dominated by high-income countries and focused on pharmacological interventions, with multinational collaboration limited to only 3% of recruiting trials.

View Article and Find Full Text PDF

[Progress on biologic therapies for severe asthma].

Zhonghua Jie He He Hu Xi Za Zhi

September 2025

Department of Allergy and Clinical Immunology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, G

Biologics play a critical role in the treatment of severe bronchial asthma. Both () and in our country recommend currently approved biologics as add-on therapies for patients whose symptoms remain uncontrolled despite high dose maintenance ICS-LABA treatments. The approved biologics include Omalizumab, Mepolizumab, Benralizumab, Reslizumab, Dupilumab, and Tezepelumab.

View Article and Find Full Text PDF

[Immune-related colitis after immune checkpoint inhibitor rechallenging: a case report].

Zhonghua Jie He He Hu Xi Za Zhi

September 2025

Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

Immune-related adverse events (irAE) are treatment-associated complications that single or multiple systems could be involved after immune checkpoint inhibitors(ICI), ranging from mild to life-threatening diseases, with significant heterogeneity. This is an important factor which might affect continuous ICI treatment. Patients who have experienced mild to moderate irAE could try ICI rechallenge after they recovered from irAE.

View Article and Find Full Text PDF

[Spontaneous remissive pulmonary sarcoidosis in a patient with a history of surgical resection of lung adenocarcinoma: a case report].

Zhonghua Jie He He Hu Xi Za Zhi

September 2025

Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.

Pulmonary patches with mediastinal lymphadenopathy could be showed in both lung cancer and sarcoidosis. There are certain similarities in their imaging manifestations, and histopathological examination is necessary for diagnosis. This article reports a case of a 62-year-old female patient who had a history of early-stage lung adenocarcinoma and underwent surgical treatment.

View Article and Find Full Text PDF

Climate change is causing a significant increase in the number of compound extreme events that pose significantly greater threats to public safety. Chongqing is a megacity in southwestern China that took the brunt of temporally compounding events (TCEs) in the summer of 2022. We developed an approach based on the Intergovernmental Panel on Climate Change (IPCC) risk framework to assess the public health risks posed by TCEs.

View Article and Find Full Text PDF